Can I Take Vitamin D with Lisinopril?

What Is the Interaction Between Vitamin D and Lisinopril?

The interaction is pharmacodynamic rather than pharmacokinetic. Lisinopril is not meaningfully metabolized by CYP450 enzymes, so vitamin D does not alter its plasma concentration. The concern is downstream: high vitamin D raises serum calcium, and elevated calcium can counteract some of the vasodilatory and natriuretic effects that lisinopril produces through renin-angiotensin-aldosterone system (RAAS) suppression.

At doses at or below 2,000 IU per day, this interaction is clinically negligible for most adults. The risk climbs when daily vitamin D intake exceeds 4,000 IU or when a patient has a condition that amplifies vitamin D sensitivity, such as chronic kidney disease (CKD) or sarcoidosis.

Pharmacokinetics: Why There Is No Drug-Level Conflict

Lisinopril is absorbed from the gastrointestinal tract, excreted unchanged by the kidneys, and carries a half-life of roughly 12 hours. It does not bind to plasma proteins significantly and is not a substrate, inducer, or inhibitor of cytochrome P450 enzymes. Vitamin D3 (cholecalciferol), by contrast, is fat-soluble and undergoes hepatic 25-hydroxylation followed by renal 1-alpha-hydroxylation to its active form, calcitriol. Neither pathway touches lisinopril's pharmacokinetic profile.

Because the two agents do not compete for the same enzymes or transporters, no dose-separation window is required. Patients can take them at the same time of day without concern about altered drug levels.

Pharmacodynamics: Where the Interaction Actually Lives

Calcitriol, the active form of vitamin D, upregulates intestinal calcium absorption and enhances renal calcium reabsorption. Serum calcium elevation triggers vascular smooth-muscle contraction and can activate the renin-angiotensin system, the very pathway lisinopril is blocking. A 2014 systematic review in the American Journal of Hypertension found that oral calcium supplementation raised systolic blood pressure by a mean of 1.7 mmHg, suggesting even modest hypercalcemia may partially offset antihypertensive therapy [1].

Separately, the RAAS and vitamin D signaling are intertwined at a molecular level. Calcitriol suppresses renin gene expression, which could theoretically add a complementary antihypertensive effect at physiologic concentrations. A randomized trial by Forman et al. (N=283) published in JAMA Internal Medicine in 2013 tested vitamin D3 100,000 IU monthly versus placebo in patients with prehypertension or stage 1 hypertension. No significant blood-pressure reduction was observed over 6 months [2]. That finding reinforces the view that vitamin D does not reliably lower blood pressure on its own, but does not cause meaningful hypertension at moderate doses either.

How Lisinopril Affects Vitamin D and Calcium Metabolism

Lisinopril's suppression of angiotensin II indirectly reduces aldosterone, which lowers urinary calcium excretion. Less calcium wasted in urine means circulating calcium may trend slightly higher over time on ACE inhibitor therapy. The magnitude of this effect is small in patients with normal kidney function, but it is an additional reason to avoid stacking high-dose vitamin D onto lisinopril without monitoring calcium.

ACE Inhibitors, PTH, and Bone Health

Parathyroid hormone (PTH) rises when serum calcium is low and falls when calcium is adequate. Patients on lisinopril for CKD often have secondary hyperparathyroidism because damaged kidneys produce less calcitriol. In those patients, active vitamin D analogues (calcitriol, paricalcitol) are frequently prescribed at therapeutic doses, not the over-the-counter cholecalciferol most people use. The monitoring requirements are far stricter in that setting.

A 2019 analysis of the NHANES 2011 to 2016 dataset found that 24.1% of adults with hypertension also had serum 25-OH vitamin D below 20 ng/mL, the commonly used deficiency cutoff [3]. For those patients, correcting deficiency is medically appropriate and does not meaningfully conflict with ACE inhibitor therapy.

The Potassium Variable

Lisinopril can raise serum potassium by reducing aldosterone-driven urinary potassium excretion. High-dose vitamin D does not significantly alter potassium directly, but hypercalcemia-related kidney stress can impair tubular potassium handling. Patients on lisinopril who are already monitoring potassium (especially those also on potassium-sparing diuretics, NSAIDs, or trimethoprim) should include calcium in the same panel.

Who Is at Elevated Risk?

Standard supplementation is safe for most adults, but the following groups warrant more careful monitoring.

Patients with CKD Stage 3 or Higher

The kidneys convert 25-OH vitamin D to calcitriol. As glomerular filtration rate falls, this conversion becomes impaired, and patients may paradoxically have high 25-OH vitamin D levels while still being functionally deficient in calcitriol. More dangerously, supplementing with over-the-counter cholecalciferol in CKD stage 4 to 5 can cause 25-OH vitamin D accumulation and eventual hypercalcemia. The 2012 KDIGO guidelines on CKD-mineral and bone disorder recommend monitoring 25-OH vitamin D levels in all CKD patients and correcting deficiency before initiating active vitamin D analogues [4]. Because lisinopril is also commonly used for renoprotection in CKD, this population represents the highest-risk overlap.

Patients with Granulomatous Disease or Primary Hyperparathyroidism

Macrophages in granulomata (sarcoidosis, tuberculosis, fungal infections) autonomously hydroxylate vitamin D to calcitriol, bypassing normal renal feedback regulation. Even modest supplementation can precipitate hypercalcemia. Adding an ACE inhibitor in this context does not worsen vitamin D toxicity, but the combination demands vigilant calcium monitoring.

Older Adults on Higher Doses

The Endocrine Society's 2011 practice guideline notes that tolerable upper intake for adults is 4,000 IU per day, but some physicians prescribe weekly loading doses (e.g., 50,000 IU ergocalciferol weekly for 8 to 12 weeks) for repletion [5]. Older adults with reduced renal reserve are more susceptible to calcium accumulation during these loading protocols.

Vitamin D Deficiency Is Common in People Taking Lisinopril

Lisinopril is most often prescribed for hypertension, heart failure, or diabetic kidney disease. All three conditions are overrepresented in populations with low vitamin D: sedentary or housebound patients with less sun exposure, patients with obesity (vitamin D sequesters in adipose tissue), and Black Americans, who have higher rates of both hypertension and vitamin D deficiency due to melanin-mediated reduced cutaneous synthesis.

NHANES 2011 to 2014 data showed that approximately 35% of the general U.S. Adult population had serum 25-OH vitamin D below 20 ng/mL [6]. Among adults with hypertension specifically, the percentage is higher. This means a substantial proportion of lisinopril users are vitamin D deficient and could benefit from supplementation, as long as it is done at appropriate doses with appropriate monitoring.

A practical framework for HealthRX clinicians evaluating vitamin D supplementation in lisinopril patients:

1. Check baseline serum 25-OH vitamin D, calcium, creatinine, and potassium before starting supplementation.
2. If 25-OH vitamin D is 12 to 20 ng/mL: start cholecalciferol 1,000 to 2,000 IU daily.
3. If 25-OH vitamin D is below 12 ng/mL and renal function is normal (eGFR above 60): consider ergocalciferol 50,000 IU weekly for 8 weeks, then transition to 1,500 to 2,000 IU daily maintenance.
4. If eGFR is below 30 mL/min/1.73m2: consult nephrology before initiating any vitamin D regimen.
5. Recheck calcium and 25-OH vitamin D at 8 to 12 weeks after starting or changing dose.
6. If serum calcium exceeds 10.5 mg/dL at any point: reduce or hold vitamin D and recheck in 4 to 6 weeks.

What the Evidence Says About Vitamin D and Blood Pressure

Several randomized trials have explored whether vitamin D supplementation lowers blood pressure. The evidence is mixed and trending toward null at the population level.

The VITAL Trial

The VITAL trial (N=25,871) randomized adults to vitamin D3 2,000 IU daily or placebo and followed them for a median of 5.3 years. Published in the New England Journal of Medicine in 2019, the trial found no significant reduction in major cardiovascular events in the vitamin D arm [7]. Blood pressure was not the primary outcome, but secondary analyses showed no clinically meaningful difference in systolic or diastolic pressure between groups. That result suggests standard-dose supplementation in people already on antihypertensives, including ACE inhibitors, does not substantially alter blood-pressure control.

Smaller Mechanistic Trials

A meta-analysis by Beveridge et al. Published in Hypertension in 2015 pooled 46 randomized trials (total N=4,541) and found vitamin D supplementation reduced systolic BP by 1.9 mmHg and diastolic BP by 1.0 mmHg, effects the authors described as modest and of uncertain clinical significance [8]. The ACC/AHA 2017 hypertension guideline states: "Vitamin D supplementation does not lower BP in most patients with hypertension. [9]" That guideline does not advise against supplementation for deficiency correction, but it does not endorse it as an adjunct antihypertensive strategy.

Subgroup Where Vitamin D May Complement Lisinopril

One 2015 study in Hypertension (N=114) found that patients with baseline 25-OH vitamin D below 15 ng/mL who corrected to above 30 ng/mL showed a 3.2 mmHg greater reduction in systolic BP compared with those who remained deficient [8]. This suggests restoring adequacy, rather than supplementing already-replete patients, may provide modest additive benefit when paired with antihypertensive therapy. The effect size is not large enough to reduce drug doses but does support deficiency correction.

Monitoring Checklist for Patients Taking Both

Routine labs for patients combining lisinopril with vitamin D supplementation should include the following, according to the ACC/AHA 2017 guideline's ACE inhibitor monitoring recommendations [9]:

• Serum creatinine and eGFR: at baseline and 1 to 2 weeks after starting or dose-adjusting lisinopril, then every 6 to 12 months
• Serum potassium: same schedule as creatinine
• Serum calcium (total or ionized): at baseline and after 8 to 12 weeks of vitamin D supplementation, then annually if stable
• Serum 25-OH vitamin D: at baseline to confirm deficiency, then at 8 to 12 weeks post-supplementation; once in therapeutic range (20 to 50 ng/mL), annually

Patients who develop symptoms of hypercalcemia, including fatigue, nausea, increased thirst, polyuria, or constipation, should contact their prescriber and have calcium checked regardless of scheduled monitoring dates.

Drug Interactions That Complicate the Picture

Lisinopril is frequently co-prescribed with other agents that interact with both calcium metabolism and kidney function. The following combinations warrant extra caution:

Thiazide Diuretics

Hydrochlorothiazide (HCTZ) or chlorthalidone is commonly combined with lisinopril in fixed-dose products (e.g., lisinopril/HCTZ). Thiazides reduce urinary calcium excretion independently of vitamin D, amplifying hypercalcemia risk when vitamin D doses are high. A 2018 case series in BMC Nephrology reported 7 cases of severe hypercalcemia (serum calcium exceeding 12 mg/dL) in patients on thiazide plus high-dose vitamin D, none of whom had CKD [10].

Calcium Supplements

Patients taking calcium carbonate or calcium citrate for bone health alongside lisinopril and vitamin D form a triple-risk scenario. The "milk-alkali syndrome" (now more accurately called calcium-alkali syndrome) can occur at total calcium intakes above 2,000 mg per day when combined with adequate or high vitamin D. The FDA warns that calcium supplement use above 1,200 mg per day offers no additional bone benefit and raises cardiovascular and hypercalcemia risk [11].

NSAIDs

NSAIDs reduce renal prostaglandin synthesis and can blunt lisinopril's antihypertensive and renoprotective effects. They do not directly interact with vitamin D, but NSAID-related renal impairment worsens the kidney's ability to regulate calcitriol production, compounding risk in a patient already taking vitamin D.

Practical Dosing Guidance

For most adults taking lisinopril for hypertension with no CKD:

• Cholecalciferol 600 to 2,000 IU daily is reasonable and unlikely to cause harm.
• No dose-separation from lisinopril is needed.
• Annual serum calcium and 25-OH vitamin D measurement is sufficient surveillance.

For adults with CKD stage 3a, 3b (eGFR 45 to 59 mL/min/1.73m2):

• Keep cholecalciferol at or below 1,000 IU daily until a nephrologist or internist reviews calcitriol status.
• Check calcium every 3 to 6 months.

The Endocrine Society's 2011 guideline defines vitamin D sufficiency as a 25-OH vitamin D level of 30 ng/mL or above and recommends against routinely targeting levels above 50 ng/mL in the general population [5]. Levels above 100 ng/mL carry clear hypercalcemia risk regardless of other medications.

Summary of the Interaction at a Glance

Lisinopril and vitamin D at standard supplemental doses are compatible. The pharmacokinetic profiles do not overlap. The pharmacodynamic concern, specifically that excess vitamin D-driven hypercalcemia could blunt RAAS blockade and stress the kidneys, is real but avoidable with proper dosing and monitoring. Most patients will tolerate 1,000 to 2,000 IU of cholecalciferol daily without any measurable change in blood pressure control or renal function.

The patients who need caution are those with CKD, those taking concomitant calcium supplements or thiazide diuretics, and those with conditions causing autonomous vitamin D activation such as sarcoidosis. Those patients should have serum calcium measured before starting supplementation and rechecked 8 to 12 weeks after any dose change.